Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3455 in Advanced Malignancies
NCT04340427Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3455 in malignant neoplasms (advanced stage), solid tumor and acute myeloid leukemia (AML), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
TQB3455
03
Conditions
malignant neoplasms (advanced stage)solid tumoracute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04340427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340427.